drugset / Trial / NCT07041203
Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor
NaSingle-groupOpen-labelTreatment
Summary
Using a comprehensive approach of clinico-behavioral testing and neuroimaging, the researchers will examine the clinical effects of the extended-release formulation of sodium oxybate on voice symptoms in spasmodic dysphonia in an open-label, proof-of-concept, dose-finding study.
Timeline
- Start
- 2026-10-01
- Primary completion
- 2027-09-30
- Completion
- 2027-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sodium Oxybate | Unknown | 1.5 g | Oral |
| Subject | Sodium Oxybate | Unknown | 2 g | Oral |
| Subject | Sodium Oxybate | Unknown | 2.5 g | Oral |
| Subject | Sodium Oxybate | Unknown | 3 g | Oral |